Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Live Updating

Invest-in-America Free

09/08/22 1:48 PM

Post #6

Re: #5: @makinezmoney - $JUNS: IPO is launching next week

JUNS (IPO):

makinezmoney Free

09/08/22 6:42 AM

Post #5

$JUNS: IPO is launching next week

We are waiting on it.

Jupiter Neurosciences, Inc. has developed the first and only resveratrol product that safely reaches therapeutic levels without GI-side effects creating treatment possibilities in many indications.

https://jupiterneurosciences.com/

GO $JUNS

Invest-in-America Free

09/04/22 1:04 PM

Post #4

JUNS: Evidently, now ready-to-go on E-Turd, Fidelity, etc.

spindog

02/03/22 12:01 PM

Post #3

Re: #2: @crudeoil24 - IPO scheduled for February 3, 2022.

Ticker hasn’t shown up on E*TRADE yet

crudeoil24 PremiumMember

02/02/22 9:46 AM

Post #2

Re: #1: @crudeoil24 - Jupiter Neurosciences, Inc., a clinical stage research and

IPO scheduled for February 3, 2022.

crudeoil24 PremiumMember

02/02/22 9:45 AM

Post #1

Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, develops resveratrol platform product primarily for the treatment of neuro-inflammation. It is developing JNS101 that is in Phase II trials for the treatment of Friedreich's Ataxia, a rare disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS102, which is in Phase II trials for the treatment of mucopolysaccharidosis Type I. The company is also developing JNS107 that is in Phase II trials for the treatment of MELAS Syndrome; and JNS108, which is in Phase II trials for the treatment of mild cognitive impairment/early Alzheimer’s disease. In addition, it is developing JNS109 for amyotrophic lateral sclerosis; JNS110 for traumatic brain injury/concussion; and JNS120 for covid-19 treatment. The company was formerly known as Jupiter Orphan Therapeutics, Inc. and changed its name to Jupiter Neurosciences, Inc. in August 2021. The company was founded in 2016 and is headquartered in Jupiter, Florida.